Most Series A rounds fail for reasons that have little to do with the underlying business. According to the venture advisory firm Burkland, founders who take any offer out of desperation, pitch investors who don't fit their stage or sector, or present a muddled story routinely create problems that surface later — often at the Series B. The pattern across investor-side commentary is consistent: the mistakes are strategic, not technical, and they cluster in three areas — how the deal is structured, who the founders target, and how the story is told.
This article organizes those failure modes into a diagnostic framework of three risk areas, each paired with the specific questions a founder can ask before the first VC meeting. One useful anchor for the deal-structure discussion comes from Carta's round benchmarking data: the median Series A dilutes founders by 18.7% of ownership, against a median post-money valuation of $76.3 million and a median round size of $14.7 million. That number gives founders a concrete reference point for judging whether a proposed round is normal — or a warning sign.
Pitfall Category 1: Deal Structure & Valuation
The most common structural mistake is chasing an inflated valuation. Allied Venture Partners, whose managing partner Matt Wilson catalogued seven recurring Series A errors, puts unrealistic valuations at the top of the list: overpricing the company can lead to down rounds and damage future fundraising. Sam Altman, writing on fundraising mistakes from his vantage at Y Combinator, makes the same point more bluntly — "The biggest problem comes from chasing high valuations," he writes, noting that YC encourages companies to seek reasonable ones.
Altman's framing is worth internalizing because it reframes what a term sheet is for. "Startups are usually a pass-fail course — either you succeed or you don't," he writes. "The important thing is to get good investors, clean terms, and not spend too much time fundraising." In other words, a valuation that maximizes this round's headline number is not the objective; a cap table and investor syndicate that keep the company fundable at the next round is.
Desperation is the other structural trap. Burkland's guidance is direct: when cash is tight, taking the first term sheet is tempting, but accepting unfavorable terms or partnering with the wrong investors creates challenges during the Series B. Founders running low on runway are the most likely to trade away control for speed — which is precisely when they should slow down and compare offers. Allied's practical recommendation is to seek at least two independent term sheets before signing, both for negotiating leverage and to establish a sense of market norms.
Pitfall Category 3: Narrative & Pitch Credibility
Investors read a pitch deck as a proxy for how the founder thinks. GoHub Ventures' fundraising guide, written by Sara Sanjuan, is explicit about this: "Your deck is more than slides; it reflects how you think and how you operate. A confusing structure, cluttered slides, unclear messaging, outdated content, or weak visual presentation can quickly undermine your credibility."
The bar is unforgiving because of volume. Investors see hundreds of decks, Sanjuan notes, and the ones that stand out are clear, thoughtful, and intentional — easy to follow, visually clean, and detailed exactly where detail is needed. Allied's guidance converges on the same discipline from the format side: keep the deck concise, roughly 10 to 13 slides, with clear and compelling data.
Two content failures compound the presentation problem. The first is weak unit economics — failing to demonstrate profitability per customer undermines investor confidence, in Allied's assessment. The second is a poor customer acquisition plan: investors need proof of a scalable, repeatable acquisition strategy, not just evidence that early customers exist. A founder who can show how the business acquires customers profitably at scale is making a different order of argument than one who can only show traction to date.
Sanjuan's summary of what separates funded founders is a useful closing test for this category: "The founders who succeed are not the ones who eliminate every risk, but the ones who make belief easy." A pitch that leaves investors doing interpretive work — reconstructing the business model, guessing at the market, or decoding the slides — is doing the opposite.
Series A Fundraising Diagnostic Framework
The three risk areas above can be turned into a self-assessment tool. The framework below maps each category to its characteristic mistake, the red flag it raises for investors, and the diagnostic question a founder should answer before outreach begins. The Carta dilution benchmark anchors the deal-structure row: at a median 18.7% dilution for a median $14.7 million round, founders can test whether a proposed deal is materially worse than market before accepting it.
| Risk area | Characteristic mistake | Investor red flag / consequence | Diagnostic question |
|---|---|---|---|
| Deal Structure & Valuation | Chasing an inflated valuation; over-optimizing terms for this round | Down rounds and damaged future fundraising, per Allied's analysis | Would I rather defend this valuation at Series B, or raise at a reasonable number with clean terms? |
| Deal Structure & Valuation | Accepting the first term sheet out of desperation | Unfavorable terms and misaligned partners create Series B challenges, per Burkland | Do I have at least two independent offers, and enough runway to compare them? |
| Deal Structure & Valuation | No reference point for what a normal round looks like | Median Series A dilution is 18.7% on a $14.7M round, per Carta's benchmarking data | Is the proposed dilution and round size within a defensible distance of market medians? |
| Investor Targeting & Alignment | Pitching investors outside the company's industry, stage, or vision | Wasted outreach and misaligned syndicates, per Allied and Burkland | Does each investor on my list have a thesis that matches my sector, stage, and vision? |
| Investor Targeting & Alignment | Treating investor selection as one-directional due diligence | Partners who offer only capital, not support, weaken the company's position | Will this investor provide support beyond capital — mentorship, connections, expertise? |
| Narrative & Pitch Credibility | A cluttered, confusing, or overcomplicated deck | Investors read the deck as a reflection of how the founder thinks and operates, per GoHub | Can a stranger follow my deck without me in the room — in 10 to 13 slides? |
| Narrative & Pitch Credibility | Weak unit economics and an unproven acquisition plan | Undermined investor confidence in scalability, per Allied | Can I show profitability per customer and a repeatable, scalable acquisition strategy? |
Used this way, the framework does more than list mistakes: it converts each one into a testable question with a known failure mode attached. A founder who answers "no" to the two-offer question, for example, knows the specific consequence they are exposed to — not an abstract risk of a bad round, but the documented pattern of Series B complications that Burkland attributes to desperation-driven terms.
Long-Term Consequences of Unfavorable Terms
The reason deal structure dominates this framework is that Series A terms lay the groundwork for every subsequent round. Allied's analysis identifies three specific provisions that create roadblocks later. Board composition changes can gradually shift control away from founders, leaving them with less decision-making power. Anti-dilution protection means that if a future round happens at a lower valuation, founders face penalties. Protective provisions — investor veto rights over major decisions — restrict operational flexibility outright.
Each of these provisions is individually negotiable and individually survivable. The danger is their cumulative effect on future fundability. Allied cites a cautionary example: founders Christina Wallace and Alex Nelson raised $1 million in 2011, and when they later pursued Series A funding, they faced rejection from VCs who felt their growth didn't meet expectations — ultimately forcing them to shut down. With venture capitalists rejecting roughly 95% of incoming deal flow, per Allied's figures, founders cannot afford to carry terms that make the next round harder to sell.
The strategic implication cuts against instinct. A founder negotiating from weakness — low runway, one offer, no alternatives — is most likely to accept the provisions that will matter most at Series B. This is why the framework places the two-offer discipline and the dilution benchmark in the same category as the valuation question: all three are defenses against the same failure, trading long-term fundability for short-term cash.
Altman's advice closes the loop. Trustworthiness matters as much as term quality: "You should be trustworthy and honest no matter what. Investors won't back you if they can't trust you." A round negotiated adversarially, or a story stretched to justify a valuation, damages the asset that outlasts any single financing — the founder's credibility with the investor community.
Your Next Step: Proactive Self-Assessment
Founders should conduct a thorough self-assessment of their fundraising strategy across deal structure, investor alignment, and narrative credibility before initiating or continuing Series A outreach. The framework above is designed for exactly that use: work through each diagnostic question, flag every "no" or "unsure," and treat each flagged item as a fixable weakness rather than a reason to delay the round.
The measurable indicator of readiness is concrete: a refined pitch deck, a targeted investor list, and a clear articulation of unit economics and long-term vision, demonstrating readiness for investor scrutiny. A founder who can pass the deck test — a stranger follows it without narration — who can name why each investor on their list fits their thesis, and who can defend their dilution against Carta's 18.7% median, has converted the three most common Series A pitfalls from liabilities into checked items before the first meeting is booked.
Sources
- 8 Series A Fundraising Mistakes to Avoid — Burkland
- Series A Funding: How to Raise Your First Priced Round — Carta
- 7 Mistakes Founders Make During Series A — Allied Venture Partners
- Fundraising Mistakes Founders Make — Sam Altman
- Common Mistakes in Startup Fundraising: Why Investors Say No — GoHub Ventures





